* All hours at time shown on the programme are TRT Turkey time (GMT +3)
Local Time Zone by Country
Athens,Greece (GMT+3)
Rotterdam,Netherlands (GMT+1)
 Shangai,China (GMT+8)
Chile,South America (GMT -3)
New Haven,USA (GMT -5)
Texas City,USA (GMT-6)
Maryland,USA
(GMT-5)
20 February 2021
HALL 1
09:30-11:00 Session I: Mesothelioma and neuroendocrine spectrum tumors
Chairs: Ismail Savas, N.Ioannis Vamvarakis
09:30-09:50 Advances in the treatment of malignant mesothelioma
Muhammet Ali Kaplan
09:50-10:10 LCNEC and the Neuroendocrine spectrum: Diagnostic pitfalls and clinical implications
Deniz Nart
10:10-10:30 SCLC: Advances in management strategies
Vassilis Ramfidis
10:30-10:45 Changing paradigms in radiotherapy management strategies for SCLC
Serap Akyurek
10:45-11:00 Discussion
11:00-11:10 Break
11:10-12:30 Session II: Optimal use of EGFR TKI
Chairs: Adnan Aydıner, Ilias Athanasiadis
11:10-11:30 Role of EGFR targeting in the adjuvant setting
Natasa Papafili
11:30-11:50 Optimal EGFR targeting in advanced disease
Mustafa Erman
11:50-12:10 Management of CNS relapse & leptomeningeal metastases
Marios Bakogeorgos
12:10-12:30: Discussion
12:30-12:40 Break
12:40-13:10 BMS Satellite – Immuno-Oncology Approach wih Nivolumab in 2L mNSCLC Treatment
Moderator: Erdem Goker
Speaker: Yesim Eralp
13:10-13:20 Break
13:20-14:35 Sesssion III: Hitting the target: Beyond EGFR
Chairs: Gokhan Demir, Sofia Agelaki
13:20-13:40 Optimal Sequencing in ALK (+) disease: Targeting resistance
Basak Oyan Uluc
13:40-14:00 Targeting ROS fusions and MET
Nuri Karadurmus
14:00-14:20 Rare mutations & Novel agents
Giannis Moutzios
14:20-14:35 Discussion
14:35-14:45 Break
14:45-15:15 Roche Diagnostics Satellite- Precision Oncology : The value of integrated diagnostics solutions along the patient journey
Moderator Erdem Goker
Speaker: Deniz Nart
15:15-15:25 Break
15:25-17:25 Sesssion IV: Immuno-oncology
Chairs: Konstantinos Syrigos, Yesim Eralp
15:25-15:45 Optimal use of IO as first line treatment in advanced NSCLC
Andriani Charpidou
15:35-16:05 Immuno-oncology in mutation driven tumors
Ilias Kotteas
16:05-16:25 What happens when IO’s fail?
Fulden Yumuk
16:25-16:45 Update on biomarkers to guide for optimal use of immune checkpoint inhibitors
Kurt Schalper
16:45-17:05 Management of immune-related adverse effects
Mehmet Altan
17:05-17:25 Discussion
17:25-17:35 Break
17:35-18:55 Session V: Multidisciplinary management of early NSCLC
Chairs: Kutsal Turhan, Ioannis Gkiozos
17:35-17:55 Diagnostic pitfalls in multiple GGO’s and partial GGO’s- synchronous
Francisco Suárez
17:55-18:15 Optimal management of multiple GGO & partial GGO’s
Shengxiang Ren
18:15-18:35 When surgery is not possible – Optimal use of SBRT in early stage disease
Deniz Yalman
18:35-18:55 Discussion
18:55-19:05 Break
19:05-20:25 Session VI: Advances in the management of locally advanced disease
Chairs: Levon Toufektzian, Ahmet Demirkazık
19:05-19:25 Neoadjuvant IO & surgery
Jessica Donington
19:25-19:45 Beyond PACIFIC – Optimal integration of IO with RT
Joechim Aerts
19:45-20:05 Advances in radiation oncology for the management of locally advanced NSCLC
Pranshu Mohindra
20:05-20:25 Discussion
20:25-20:35 Break
20:35-21:05 Session VII Live Discussion: COVID & the Lung Cancer Patient
Erdem Goker,Deniz Koksal, Christian Rolfo, Garyfallia Poulakou, Maria Toki,Semih Halezeroglu
Closing Remarks